EP1242049A4 - Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i - Google Patents

Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Info

Publication number
EP1242049A4
EP1242049A4 EP00986510A EP00986510A EP1242049A4 EP 1242049 A4 EP1242049 A4 EP 1242049A4 EP 00986510 A EP00986510 A EP 00986510A EP 00986510 A EP00986510 A EP 00986510A EP 1242049 A4 EP1242049 A4 EP 1242049A4
Authority
EP
European Patent Office
Prior art keywords
associated antigen
hla class
tumor associated
vaccine compositions
antigen peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00986510A
Other languages
German (de)
English (en)
Other versions
EP1242049A1 (fr
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Esteban Celis
Elissa Keogh
Robert Chesnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,608 external-priority patent/US6602510B1/en
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1242049A1 publication Critical patent/EP1242049A1/fr
Publication of EP1242049A4 publication Critical patent/EP1242049A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP00986510A 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i Withdrawn EP1242049A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US543608 1995-10-16
US17044899P 1999-12-13 1999-12-13
US170448P 1999-12-13
US09/543,608 US6602510B1 (en) 2000-04-05 2000-04-05 HLA class I A2 tumor associated antigen peptides and vaccine compositions
US58320000A 2000-05-30 2000-05-30
US583200 2000-05-30
PCT/US2000/034318 WO2001041741A1 (fr) 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Publications (2)

Publication Number Publication Date
EP1242049A1 EP1242049A1 (fr) 2002-09-25
EP1242049A4 true EP1242049A4 (fr) 2005-01-05

Family

ID=27389823

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00986510A Withdrawn EP1242049A4 (fr) 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Country Status (5)

Country Link
EP (1) EP1242049A4 (fr)
JP (1) JP2003516344A (fr)
AU (1) AU2273701A (fr)
CA (1) CA2393730A1 (fr)
WO (1) WO2001041741A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343819A4 (fr) * 2000-09-01 2005-03-23 Epimmune Inc Peptides de fixation de hla-a2.1 et leurs utilisations
EP1903056A3 (fr) * 2002-12-10 2008-05-07 Idm Pharma, Inc. Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
US20060094649A1 (en) * 2002-12-10 2006-05-04 Keogh Elissa A Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions
MXPA05006113A (es) * 2002-12-11 2005-09-30 Pharmexa As Epitopos sencillos objetivo.
US20080274129A1 (en) * 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
EP1676132B1 (fr) 2003-10-21 2014-01-22 Cedars-Sinai Medical Center La combinaison de la chimiothérapie et de l'administration de cellules dendritiques pulsée avev gliome antigènes dans le traitement du gliome
WO2008039874A2 (fr) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Vaccins comprenant des antigènes de cellules souches cancéreuses et procédés
WO2008039969A2 (fr) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Vaccins contre le cancer et méthodes de vaccination
WO2009059011A2 (fr) * 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Peptides de liaison hla-dr et leurs utilisations
EP2328923B1 (fr) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Épitopes cd133
JP5792630B2 (ja) * 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
US9764012B2 (en) * 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
WO2010129895A2 (fr) 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Epitopes des cd133
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
JP2014169280A (ja) * 2013-02-05 2014-09-18 Nitto Denko Corp 経皮または粘膜投与用ワクチン組成物
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
RU2627175C2 (ru) * 2013-03-08 2017-08-03 Тайхо Фармасьютикал Ко., Лтд. Новый пептид, имеющий 5 соединенных эпитопов ctl
EP3028048B1 (fr) 2013-07-31 2018-09-26 BioVentures, LLC Compositions permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur
TWI651094B (zh) 2013-10-21 2019-02-21 日商大鵬藥品工業股份有限公司 新穎ｃｔｌ抗原決定部位４連結肽
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
KR102663596B1 (ko) 2017-04-26 2024-05-10 유레카 쎄라퓨틱스, 인코포레이티드 글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
EP1012238A4 (fr) * 1997-01-31 2003-03-05 Epimmune Inc Cellules a peptides ou a antigenes charges de peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP1242049A1 (fr) 2002-09-25
WO2001041741A1 (fr) 2001-06-14
JP2003516344A (ja) 2003-05-13
AU2273701A (en) 2001-06-18
WO2001041741A9 (fr) 2002-05-30
CA2393730A1 (fr) 2001-06-14

Similar Documents

Publication Publication Date Title
EP1242049A4 (fr) Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i
PT1620456E (pt) Péptidos antigénicos hla-a2 associados a tumor e suas composições
PT1150712E (pt) Formulações para a vacina do vírus do papiloma humano
NL300415I1 (nl) Vaccin tegen antigenen van bacteriën
HK1048435A1 (en) Combined vaccine compositions
IL125608A0 (en) Tumor associated antigen peptides and use of same as anti-tumor vaccines
LU91326I2 (fr) Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
PL392363A1 (pl) Kompozycja szczepionki
IL148247A (en) Vaccine and its uses
AP2002002424A0 (en) Vaccine
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
IL189736A0 (en) Vaccine adjuvants
HK1051544A1 (en) Novel hev antigenic peptide and methods
AU5913801A (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
IL145440A0 (en) Synthetic hcv envelope proteins and their use for vaccination
GB9906437D0 (en) Vaccine
NO996412D0 (no) Antigene peptider
GB9921242D0 (en) Cancer vaccine and diagnosis
HK1047116A1 (zh) 來自mage的免疫原性肽及其應用
GB9911824D0 (en) New vaccine formulations
GB9911825D0 (en) New vaccine formulations
IL141093A0 (en) Tumor associated antigen peptides and use of same as anti-tumor vaccines
GB9930456D0 (en) Vaccine compositions
GB9930461D0 (en) Vaccine compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041119

17Q First examination report despatched

Effective date: 20070823

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080304